British journal of cancer
Journal
Overview
publication venue for
-
Correction to: EGFR/Ras-induced CCL20 production modulates the tumour microenvironment.
2021
-
Correction: Camptothecin suppresses NRF2-ARE activity and sensitises hepatocellular carcinoma cells to anticancer drugs.
2019
-
Recurrent somatic mutations of FAT family cadherins induce an aggressive phenotype and poor prognosis in anaplastic large cell lymphoma.
2024
-
Hit it hard: qualitative patient perspectives on the optimisation of immune checkpoint inhibition..
131.
2024
-
Associations of stem cell markers CD44, CD24 and ALDH1A1 with mammographic breast density in women with benign breast biopsies.
2024
-
Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom..
130.
2024
-
Outcomes of relapsed clinical stage I versus de novo metastatic testicular cancer patients: an analysis of the IGCCCG Update database.
2023
-
A metabolomic analysis of adiposity measures and pre- and postmenopausal breast cancer risk in the Nurses' Health Studies.
2022
-
Association between physical activity and neoadjuvant chemotherapy completion and pathologic complete response in primary breast cancer: the CANTO study.
2022
-
Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma.
2022
-
Immune biomarkers and response to checkpoint inhibition of BRAFV600 and BRAF non-V600 altered lung cancers..
126.
2021
-
Exploiting mesothelin in thymic carcinoma as a drug delivery target for anetumab ravtansine.
2021
-
Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancer.
2021
-
Cardiovascular mortality among cancer survivors who developed breast cancer as a second primary malignancy.
2021
-
Mendelian randomisation study of smoking exposure in relation to breast cancer risk.
2021
-
Mammographic microcalcifications and risk of breast cancer..
125.
2021
-
TP53 mutations increase radioresistance in rhabdomyosarcoma and Ewing sarcoma..
125.
2021
-
A phase 1/2 trial of ibrutinib in combination with pembrolizumab in patients with mismatch repair proficient metastatic colorectal cancer..
124.
2021
-
CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers..
124.
2021
-
Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma..
124.
2021
-
EGFR/Ras-induced CCL20 production modulates the tumour microenvironment..
123.
2020
-
A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma..
122.
2019
-
Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer..
122.
2019
-
Retinoid X receptor gamma (RXRG) is an independent prognostic biomarker in ER-positive invasive breast cancer..
121.
2019
-
Claudin-18 expression in oesophagogastric adenocarcinomas: a tissue microarray study of 523 molecularly profiled cases..
121.
2019
-
A key genomic subtype associated with lymphovascular invasion in invasive breast cancer..
120.
2019
-
Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study..
120.
2019
-
A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours..
119.
2018
-
North American population-based validation of the National Comprehensive Cancer Network Practice Guideline Recommendations for locoregional lymph node and bone imaging in prostate cancer patients..
119.
2018
-
Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma..
119.
2018
-
Impact of race on dose selection of molecular-targeted agents in early-phase oncology trials..
118.
2018
-
Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma..
118.
2018
-
Integrating cytokines and angiogenic factors and tumour bulk with selected clinical criteria improves determination of prognosis in advanced renal cell carcinoma..
117.
2017
-
Radiation-associated breast cancer and gonadal hormone exposure: a report from the Childhood Cancer Survivor Study..
117.
2017
-
Examining the common aetiology of serous ovarian cancers and basal-like breast cancers using double primaries..
116.
2017
-
Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR+, HER2- advanced breast cancer: results from BOLERO-2..
116.
2017
-
Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer..
116.
2017
-
Reproductive and hormonal factors in relation to survival and platinum resistance among ovarian cancer cases..
115.
2016
-
Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer..
115.
2016
-
Cardiorespiratory fitness in long-term lymphoma survivors after high-dose chemotherapy with autologous stem cell transplantation..
115.
2016
-
Prospective changes in global DNA methylation and cancer incidence and mortality..
115.
2016
-
Statin use and all-cancer survival: prospective results from the Women's Health Initiative..
115.
2016
-
Validation of a contemporary prostate cancer grading system using prostate cancer death as outcome..
114.
2016
-
Adjuvant ovarian function suppression and cognitive function in women with breast cancer..
114.
2016
-
Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array..
114.
2016
-
Pre-diagnostic circulating sex hormone levels and risk of prostate cancer by ERG tumour protein expression..
114.
2016
-
Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma..
114.
2016
-
Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markers..
114.
2015
-
Prognostic significance of PET assessment of metabolic response to therapy in oesophageal squamous cell carcinoma..
113.
2015
-
Histopathological features of papillary thyroid carcinomas detected during four screening examinations of a Ukrainian-American cohort..
113.
2015
-
Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients..
113.
2015
-
Postmenopausal mammographic breast density and subsequent breast cancer risk according to selected tissue markers..
113.
2015
-
MC1R gene variants and non-melanoma skin cancer: a pooled-analysis from the M-SKIP project..
113.
2015
-
Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort..
113.
2015
-
An analysis of the association between prostate cancer risk loci, PSA levels, disease aggressiveness and disease-specific mortality..
113.
2015
-
Hypoxia-activated chemotherapeutic TH-302 enhances the effects of VEGF-A inhibition and radiation on sarcomas..
113.
2015
-
IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma..
112.
2015
-
Effect of aerobic training on the host systemic milieu in patients with solid tumours: an exploratory correlative study..
112.
2015
-
Recurrent osteosarcoma with a single pulmonary metastasis: a multi-institutional review..
112.
2014
-
Drug withdrawal in women with progressive metastatic breast cancer while on aromatase inhibitor therapy..
111.
2014
-
Pretherapeutic gamma-glutamyltransferase is an independent prognostic factor for patients with renal cell carcinoma..
111.
2014
-
Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error..
111.
2014
-
Clinical nodal staging scores for prostate cancer: a proposal for preoperative risk assessment..
111.
2014
-
Population-based comparison of prognostic factors in invasive micropapillary and invasive ductal carcinoma of the breast..
111.
2014
-
Safety and efficacy of resistance training in germ cell cancer patients undergoing chemotherapy: a randomized controlled trial..
111.
2014
-
Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial..
110.
2014
-
Breast cancer risk after radiotherapy for heritable and non-heritable retinoblastoma: a US-UK study..
110.
2014
-
Focal amplification of the androgen receptor gene in hormone-naive human prostate cancer..
110.
2014
-
Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma..
110.
2014
-
First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer..
109.
2013
-
High-risk features in radiation-associated breast angiosarcomas..
109.
2013
-
Aromatase inhibitor-induced modulation of breast density: clinical and genetic effects..
109.
2013
-
Lymph node density in oral cavity cancer: results of the International Consortium for Outcomes Research..
109.
2013
-
Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder..
109.
2013
-
Stromal disrupting effects of nab-paclitaxel in pancreatic cancer..
109.
2013
-
A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas..
109.
2013
-
IRF-1 responsiveness to IFN-γ predicts different cancer immune phenotypes..
109.
2013
-
Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma..
108.
2013
-
Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer..
108.
2013
-
Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial..
108.
2013
-
Prognostic value of Ki-67 for prostate cancer death in a conservatively managed cohort..
108.
2013
-
Mir143 expression inversely correlates with nuclear ERK5 immunoreactivity in clinical prostate cancer..
108.
2013
-
Endocervical glandular neoplasia associated with lobular endocervical glandular hyperplasia is HPV-independent and correlates with carbonic anhydrase-IX expression: a Gynaecological Oncology Group Study..
108.
2013
-
Risk stratification of pT1-3N0 patients after radical cystectomy for adjuvant chemotherapy counselling..
107.
2012
-
Somatic MED12 mutations in uterine leiomyosarcoma and colorectal cancer..
107.
2012
-
Mismatch repair deficiency: a temozolomide resistance factor in medulloblastoma cell lines that is uncommon in primary medulloblastoma tumours..
107.
2012
-
Dynamic changes of live/apoptotic circulating tumour cells as predictive marker of response to sunitinib in metastatic renal cancer..
107.
2012
-
Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma..
107.
2012
-
Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-α..
106.
2012
-
Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis..
106.
2012
-
Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort..
106.
2012
-
Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma..
106.
2012
-
Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC)..
106.
2012
-
Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort..
105.
2011
-
miR-21 and miR-155 are associated with mitotic activity and lesion depth of borderline melanocytic lesions..
105.
2011
-
Genetic architecture of prostate cancer in the Ashkenazi Jewish population..
105.
2011
-
A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma..
105.
2011
-
XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results..
105.
2011
-
Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)..
104.
2011
-
Recurrence and survival after pathologic complete response to preoperative therapy followed by surgery for gastric or gastrooesophageal adenocarcinoma..
104.
2011
-
Carbonic anhydrase IX (CA-IX) and high-risk human papillomavirus (H-HPV) as diagnostic biomarkers of cervical dysplasia/neoplasia in Japanese women with a cytologic diagnosis of atypical glandular cells (AGC): a Gynecologic Oncology Group (GOG) Study..
104.
2010
-
A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma..
103.
2010
-
Prognostic significance of AMP-activated protein kinase expression and modifying effect of MAPK3/1 in colorectal cancer..
103.
2010
-
A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands..
103.
2010
-
Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer..
103.
2010
-
Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case-control study..
103.
2010
-
Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer..
102.
2010
-
Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-alpha in a phase III trial: final results and geographical analysis..
102.
2010
-
Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer..
102.
2010
-
Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapy..
102.
2009
-
Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA)..
101.
2009
-
Circulating tumour cells are associated with increased risk of venous thromboembolism in metastatic breast cancer patients..
101.
2009
-
Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial..
101.
2009
-
Cannabis, tobacco and domestic fumes intake are associated with nasopharyngeal carcinoma in North Africa..
101.
2009
-
Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangement..
101.
2009
-
Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study..
100.
2009
-
Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients..
100.
2008
-
Dynamic change in phosphorylated platelet-derived growth factor receptor in peripheral blood leukocytes following docetaxel therapy predicts progression-free and overall survival in prostate cancer..
99.
2008
-
Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer..
99.
2008
-
Risk for contralateral breast cancer among carriers of the CHEK2*1100delC mutation in the WECARE Study..
98.
2008
-
Combined modality chemoradiation in elderly oesophageal cancer patients..
96.
2007
-
Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy..
96.
2007
-
Joint association of polymorphism of the FGFR4 gene and mutation TP53 gene with bladder cancer prognosis..
95.
2006
-
Long-term outcome among men with conservatively treated localised prostate cancer..
95.
2006
-
Phase I and pharmacokinetic study of the novel chemoprotector BNP7787 in combination with cisplatin and attempt to eliminate the hydration schedule..
92.
2005
-
Adenoviral vector-mediated expression of a gene encoding secreted, EpCAM-targeted carboxylesterase-2 sensitises colon cancer spheroids to CPT-11..
92.
2005
-
Function and quality-of-life of survivors of pelvic and lower extremity osteosarcoma and Ewing's sarcoma: the Childhood Cancer Survivor Study..
91.
2004
-
Comprehensive analysis of the 9p21 region in neuroblastoma suggests a role for genes mapping to 9p21-23 in the biology of favourable stage 4 tumours..
91.
2004
-
The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website..
91.
2004
-
Downregulation of Bcl-2 sensitises interferon-resistant renal cancer cells to Fas..
91.
2004
-
Overexpression of Bcl2 abrogates chemo- and radiotherapy-induced sensitisation of NCI-H460 non-small-cell lung cancer cells to adenovirus-mediated expression of full-length TRAIL..
91.
2004
-
Small-cell carcinoma of the gastrointestinal tract: a retrospective study of 64 cases..
90.
2004
-
Glutathione S-transferases (GSTT1 and GSTM1) gene deletions in Tunisians: susceptibility and prognostic implications in breast carcinoma..
89.
2003
-
Elevated protein kinase C alpha expression may be predictive of tamoxifen treatment failure..
88.
2003
-
Vascular patterns in reactive lymphoid tissue and in non-Hodgkin's lymphoma..
88.
2003
-
A phase II study of active specific immunotherapy and 5-FU/Leucovorin as adjuvant therapy for stage III colon carcinoma..
86.
2002
-
Accelerated cisplatin and high-dose epirubicin with G-CSF support in patients with relapsed non-small-cell lung cancer: feasibility and efficacy..
85.
2001
-
hTR repressor-related gene on human chromosome 10p15.1..
85.
2001
-
Genetic heterogeneity and clonal evolution in neuroblastoma..
85.
2001
-
Allelic loss of 10q23, the PTEN tumour suppressor gene locus, in Barrett's oesophagus-associated adenocarcinoma..
84.
2001
-
Telomerase activity in plasma cell dyscrasias..
84.
2001
-
Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines..
83.
2000
-
Monoclonal antibody MA454 reveals a heterogeneous expression pattern of MAGE-1 antigen in formalin-fixed paraffin embedded lung tumours..
83.
2000
-
Analysis of the insertion/deletion polymorphism of the human angiotensin converting enzyme (ACE) gene in patients with renal cancer..
82.
2000
-
The prevalence of BRCA1 mutations in Chinese patients with early onset breast cancer and affected relatives..
82.
2000
-
p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy..
82.
2000
-
In vivo fluorescence imaging of the transport of charged chlorin e6 conjugates in a rat orthotopic prostate tumour..
81.
1999
-
Wheatgerm agglutinin-mediated toxicity in pancreatic cancer cells..
80.
1999
-
Characterization of human soft-tissue sarcoma xenografts for use in secondary drug screening..
78.
1998
-
The effects of norethisterone on endometrial abnormalities identified by transvaginal ultrasound screening of healthy post-menopausal women on tamoxifen or placebo..
78.
1998
-
Determinants of CPT-11 and SN-38 activities in human lung cancer cells..
77.
1998
-
Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: outcome and clinical implications..
77.
1998
-
Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer..
77.
1998
-
CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein..
77.
1998
-
A phase I/II study of leucovorin, carboplatin and 5-fluorouracil (LCF) in patients with carcinoma of unknown primary site or advanced oesophagogastric/pancreatic adenocarcinomas..
75.
1997
-
Resection of residual retroperitoneal masses in testicular cancer: evaluation and improvement of selection criteria. The ReHiT study group. Re-analysis of histology in testicular cancer..
74.
1996
-
Survival of patients with advanced urothelial cancer treated with cisplatin-based chemotherapy..
74.
1996
-
Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group..
74.
1996
-
Radioimmunotherapy of colorectal carcinoma xenografts in nude mice with yttrium-90 A33 IgG and Tri-Fab (TFM)..
74.
1996
-
p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer..
74.
1996
-
Altered patterns of retinoblastoma gene product expression in adult soft-tissue sarcomas..
72.
1995
-
DT-diaphorase activity in normal and neoplastic human tissues; an indicator for sensitivity to bioreductive agents?.
72.
1995
-
Platinum-Taxol non-cross resistance in epithelial ovarian cancer..
71.
1995
-
Family history of cancer, body weight, and p53 nuclear overexpression in Duke's C colorectal cancer..
71.
1995
-
Docetaxel (Taxotere), a novel taxoid, in the treatment of advanced colorectal carcinoma: an EORTC Early Clinical Trials Group Study..
70.
1994
-
Cortisol is transported by the multidrug resistance gene product P-glycoprotein..
67.
1993
-
Growth, morphology and chemosensitivity studies on postconfluent cells cultured in 'V'-bottomed microtiter plates..
66.
1992
-
Increased expression of differentiation markers can accompany laminin-induced attachment of small cell lung cancer cells..
66.
1992
-
Preliminary observations on the microdistribution of labelled antibodies in human colonic adenocarcinoma xenografts: relevance to microdosimetry..
61.
1990
-
Monoclonal antibody 3F8 recognises the neural cell adhesion molecule (NCAM) in addition to the ganglioside GD2..
60.
1989
-
Mitomycin C, vinblastine and cis-platin. An active regimen for advanced non-small cell lung cancer..
56.
1987
-
Superior therapeutic activity of liposome-associated adriamycin in a murine metastatic tumour model..
51.
1985
-
Restoration of doxorubicin responsiveness in doxorubicin-resistant P388 murine leukaemia cells..
50.
1984
-
Retinoma: spontaneous regression of retinoblastoma or benign manifestation of the mutation?.
45.
1982
-
NMR in cancer, XIII: application of the NMR malignancy index to human mammary tumours..
38.
1978
-
Nuclear magnetic resonance in cancer, XII: Application of NMR malignancy index to human lung tumours..
36.
1977
-
Reply to Comment on 'Statin use and all-cancer survival: prospective results from the Women's Health Initiative'..
116.
2016
-
AMD3100/Plerixafor overcomes immune inhibition by the CXCL12-KRT19 coating on pancreatic and colorectal cancer cells.
2021
-
Reply: 'Comments on Stromal disrupting effects of nab-paclitaxel in pancreatic cancer'.
2014
-
Lessons from the SWITCH trial: changing glucocorticoids in the management of metastatic castration-resistant prostate cancer (mCRPC)..
119.
2018
-
Combination VEGFR/immune checkpoint inhibitor therapy: a promising new treatment for renal cell carcinoma..
119.
2018
-
Promoting exercise after a cancer diagnosis: easier said than done..
110.
2014
-
Cancer metastasis as a non-healing wound.
2021
-
Cancer health disparities in racial/ethnic minorities in the United States.
2020
-
Immune modulation for cancer therapy.
2014
-
HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development.
2014
-
"Stromal cells in prostate cancer pathobiology: friends or foes?".
2022
-
Circulating tumour cells in the -omics era: how far are we from achieving the 'singularity'?
2022
-
Reprogramming of fatty acid metabolism in cancer.
2019
-
Comparing comparators: a look at control arms in kidney cancer studies over the years.
2014
-
The AURORA initiative for metastatic breast cancer.
2014
Identity
ISO Abbreviation
Linking ISSN
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)